In NIAGARA (NCT03732677), addition of perioperative D to neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) demonstrated a significant improvement in event-free survival (EFS) and overall survival and a numerical increase in pathological complete response (pCR) vs NAC and RC alone in pts with MIBC. In a prior exploratory analysis, negative plasma ctDNA status after neoadjuvant treatment prior to RC (pre-RC) was associated with prolonged EFS but not pCR. Here we assess utDNA as a complementary approach in this setting. Methods: Cisplatin-eligible pts with MIBC (cT2-T4aN0/1M0) were randomized 1:1 to receive perioperative D plus NAC (cisplatin + gemcitabine) and RC (D arm) or NAC and RC alone (comparator [C] arm). Dual primary endpoints were EFS and pCR. Exploratory analysis of utDNA and ctDNA was completed using the personalized Signatera assay (Natera, Inc, Austin, TX, USA) at baseline (BL; n=205) and pre-RC (n=183). Results: Of 1063 pts, 265 (25%) comprised the biomarker-evaluable population (BEP; 134 D arm; 131 C arm). At BL, lower utDNA levels were associated with longer EFS (low vs high utDNA HR 0.65, 95% CI 0.40−1.04). From BL to pre-RC, utDNA+ rate decreased from 85% to 55%. utDNA clearance was associated with longer EFS (HR 0.24, 95% CI 0.09−0.62) and was 12% higher in the D vs C arm (39% vs 27%). Pre-RC utDNA status was associated with a pCR (utDNA−; 72% [55/76] vs utDNA+; 18% [17/96]). Pre-RC utDNA and ctDNA status differentially correlated with disease stage at RC, with utDNA+ correlating with noninvasive disease (
Urinary tumor DNA (utDNA) and circulating tumor DNA (ctDNA) in patients (pts) with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA / Van Der Heijden, M.S., Galsky, M.D., Joshi, R., Catto, J.W.F., Meeks, J.J., Nishiyama, H., Al-Ahmadie, H., Antonuzzo, L., Quang, T.V.U., Zakharia, Y., Atduev, V., Eigl, B.J., Suárez, C., Ho, S., Xiong, H., Moeini Mortazavi, A., Shrestha, Y., Powles, T.. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - ELETTRONICO. - 44:(2026), pp. 636-636. [10.1200/jco.2026.44.7_suppl.636]
Urinary tumor DNA (utDNA) and circulating tumor DNA (ctDNA) in patients (pts) with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA
Antonuzzo, Lorenzo;
2026
Abstract
In NIAGARA (NCT03732677), addition of perioperative D to neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) demonstrated a significant improvement in event-free survival (EFS) and overall survival and a numerical increase in pathological complete response (pCR) vs NAC and RC alone in pts with MIBC. In a prior exploratory analysis, negative plasma ctDNA status after neoadjuvant treatment prior to RC (pre-RC) was associated with prolonged EFS but not pCR. Here we assess utDNA as a complementary approach in this setting. Methods: Cisplatin-eligible pts with MIBC (cT2-T4aN0/1M0) were randomized 1:1 to receive perioperative D plus NAC (cisplatin + gemcitabine) and RC (D arm) or NAC and RC alone (comparator [C] arm). Dual primary endpoints were EFS and pCR. Exploratory analysis of utDNA and ctDNA was completed using the personalized Signatera assay (Natera, Inc, Austin, TX, USA) at baseline (BL; n=205) and pre-RC (n=183). Results: Of 1063 pts, 265 (25%) comprised the biomarker-evaluable population (BEP; 134 D arm; 131 C arm). At BL, lower utDNA levels were associated with longer EFS (low vs high utDNA HR 0.65, 95% CI 0.40−1.04). From BL to pre-RC, utDNA+ rate decreased from 85% to 55%. utDNA clearance was associated with longer EFS (HR 0.24, 95% CI 0.09−0.62) and was 12% higher in the D vs C arm (39% vs 27%). Pre-RC utDNA status was associated with a pCR (utDNA−; 72% [55/76] vs utDNA+; 18% [17/96]). Pre-RC utDNA and ctDNA status differentially correlated with disease stage at RC, with utDNA+ correlating with noninvasive disease (I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.



